TheEdgeResearch
Home / Stocks / BVNRY

Bavarian Nordic A/S (BVNRY)

OTC Healthcare Biotechnology
$11.87 ▲ +1.19%
Market Cap
$2.84B
Sector
Healthcare
Industry
Biotechnology
Beta
0.94
52-Wk Range
8.67-12.72
CEO
Tarja Stenvall
Country
DK
Currency
USD

Bavarian Nordic A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Hellerup, CR, DK. The stock last traded at $11.87, up 1.19% on the session, giving a market capitalisation of $2.84B. On trailing twelve-month figures it carries a trailing P/E of 20.48, a net margin of 14.2%. Its beta of 0.94 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
20.48
Price / Sales
2.93
Price / Book
1.37
EV / EBITDA
9.22
Gross margin
50.0%
Operating margin
18.3%
Net margin
14.2%
Return on equity
—
Debt / equity
0.01
Current ratio
6.56
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1,795
IPO date
2013-04-03
Headquarters
Hellerup, CR, DK
About Bavarian Nordic A/S

Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.

Comparable companies

Bavarian Nordic A/S is most often compared with the following Healthcare names:

ARCTBNTXCVMMRNANVAXOGENPCVXVALNVIRVXRT
More research on BVNRY
BVNRY technical analysis BVNRY TheEdge Score Compare against peers
Open full interactive analysis & DCF →